Penn Capital Management Company LLC Takes Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Penn Capital Management Company LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 4th quarter, Holdings Channel.com reports. The fund purchased 131,794 shares of the medical equipment provider’s stock, valued at approximately $11,790,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. lifted its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after acquiring an additional 435,445 shares during the period. Reinhart Partners LLC. boosted its stake in shares of Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Lantheus by 2.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider’s stock worth $120,510,000 after buying an additional 30,891 shares during the period. Swedbank AB raised its stake in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after buying an additional 385,000 shares during the last quarter. Finally, Portolan Capital Management LLC lifted its holdings in Lantheus by 21.1% in the fourth quarter. Portolan Capital Management LLC now owns 812,630 shares of the medical equipment provider’s stock valued at $72,698,000 after buying an additional 141,749 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Truist Financial raised their price objective on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 63,109 shares of company stock worth $6,016,046. 2.00% of the stock is owned by corporate insiders.

Lantheus Stock Performance

NASDAQ:LNTH opened at $101.20 on Thursday. Lantheus Holdings, Inc. has a 52 week low of $63.61 and a 52 week high of $126.89. The firm has a 50-day moving average price of $96.54 and a two-hundred day moving average price of $95.40. The firm has a market cap of $6.93 billion, a price-to-earnings ratio of 16.84 and a beta of 0.20.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.